CHI Immunogenicity Summit 8 October 2020 Presentation

 

Optimizing ADA assay tolerance towards drug product using automated acid dissociation in an automated, microfluidic format

Recently, regulatory agencies have lowered sensitivity requirements for anti-drug antibody (ADA) bioassays. Reaching lower sensitivity levels while maintaining drug tolerance may necessitate lengthy acid dissociation pre-treatment steps, affecting assay quality. We present miniaturized, microfluidic ADA immunoassays with an automated acid dissociation step that demonstrate high sensitivity, high-quality, and drug-tolerant assays.

 

Speaker:

John-Chappell-3-150x150

John Chappell, BSc, CChem, CSci, FRSC
Application & Service Director
EMEA and Asia Pacific
Gyros Protein Technologies

 

 

 

If you have problems to view the webinar please contact maritha.lundin@gyrosproteintech.com

 

Please register to access the webinar